Predictors of Initial and Sustained Remission in Patients Treated with Antithyroid Drugs for Graves' Hyperthyroidism:The RISG Study by Karmisholt, J. et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Predictors of Initial and Sustained Remission in Patients Treated with Antithyroid
Drugs for Graves' Hyperthyroidism
The RISG Study
Karmisholt, J.; Andersen, S. L.; Bulow-Pedersen, I.; Carlé, A.; Krejbjerg, A.; Nygaard, B.
Published in:
Journal of Thyroid Research
DOI:
10.1155/2019/5945178
Publication date:
2019
Document license:
CC BY
Citation for published version (APA):
Karmisholt, J., Andersen, S. L., Bulow-Pedersen, I., Carlé, A., Krejbjerg, A., & Nygaard, B. (2019). Predictors of
Initial and Sustained Remission in Patients Treated with Antithyroid Drugs for Graves' Hyperthyroidism: The
RISG Study. Journal of Thyroid Research, 2019, [5945178]. https://doi.org/10.1155/2019/5945178
Download date: 14. May. 2020
Research Article
Predictors of Initial and Sustained Remission in
Patients Treated with Antithyroid Drugs for Graves’
Hyperthyroidism: The RISG Study
J. Karmisholt ,1,2 S. L. Andersen ,3 I. Bulow-Pedersen,1,2 A. Carlé,1
A. Krejbjerg ,4 and B. Nygaard5
1Dept. of Endocrinology, Aalborg University Hospital, 9000 Aalborg, Denmark
2Dept. of Clinical Institute, Aalborg University, 9100 Aalborg, Denmark
3Dept. of Clinical Biochemistry, Aalborg University Hospital, 9000 Aalborg, Denmark
4Dept. of Oncology, Aalborg University Hospital, 9000 Aalborg, Denmark
5Dept. of Endocrinology and Internal Medicine, Herlev Hospital, 2730 Copenhagen, Denmark
Correspondence should be addressed to J. Karmisholt; jsk@rn.dk
Received 5 September 2018; Revised 14 November 2018; Accepted 2 December 2018; Published 3 January 2019
Academic Editor: Noriyuki Koibuchi
Copyright © 2019 J. Karmisholt et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Purpose. To study predictors of attaining (part 1) and sustaining (part 2) remission in patients with Graves’ hyperthyroidism (GH)
treated with antithyroid drugs (ATD). Methods. In the prospective first part, the included patients were treated with ATD until a
prespecified definition of remission (thyrotropin > 0.4mU/L and TSH-receptor antibodies (TRAb)≤ 1. 0 IU/L in a patient receiving
a methimazole dose ≤ 5 mg/day, on two occasions two months apart) was met, or for 24 months. In the second part, patients
attaining remission in part 1 were randomized to treatment or observation and followed until relapse or for 24 months. Results. 173
patients completed study 1 and 53% attained remission. TRAb and age were the only significant predictors of remission. Patients
with baseline TRAb below vs above 10 IU/L attained remission in 63% compared to 39%, and 5 months priorly (p<0.001). In study
2, 96.4% of the patients randomized to treatment (n=33) sustained remission compared to 66% in the observation group (n=33).
Treatment arm was the only significant parameter (p<0.001) of sustained remission. Conclusion. Baseline TRAb was prognostic for
attaining remission in GH. Consecutive TRAb measurements during treatment were not worthwhile, but a single measurement
after 6-8 months in patients with initial TRAb < 10 IU/L could substantially shorten the treatment period in a subgroup of patients.
Only 3.6% of the patients in remission experienced relapse during follow-up when treated with a combination of fixed low dose
methimazole and L-T4. ClinTrial.gov registration number is NCT00796913.
1. Introduction
Thyrotoxicosis including Graves’ hyperthyroidism (GH)
affects many people worldwide [1–3]. Diagnosing GH is
often straightforward, whereas treatment may be challeng-
ing. Attaining and sustaining remission is the main goal
when treating GH [4, 5]. In most patients, remission is
achievable with antithyroid drug (ATD) therapy. However,
sustaining a remission after stopping ATD has proven to be
more challenging as relapse is seen in around 50% of GH
patients after discontinuing ATD [6–9]. Studies, investigating
both type and dose of ATD as well as different treatment
durations, show that titration therapy with methimazole for
12–18 months is the treatment of choice [9, 10]. This is in
line with the recent American and European guidelines on
hyperthyroidism [4, 5]. However, ATD treatment also has
side effects which may be severe and even fatal [11]. Inducing
a hypothyroid state when treating GHmay activate or aggra-
vate Graves’ orbitopathy and should be avoided [12, 13]. At the
disease onset, it is difficult to identify which patientswill enter
remission during a standard course of ATD treatment. In
clinical practice, GH is a disease with highly variable clinical
presentation and prognostic outcome. Hence, monitoring
treatment with regular measurements of thyroid hormones is
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necessary to avoid over- or undertreatment. Thus, it is impor-
tant to optimize the control program during ATD treatment
and to identify if there are subgroups of patients who could
benefit from a shorter or longer treatment duration compared
to the standard treatment period.
The present study comprises two parts and is termed the
“Remission Induction and Sustenance in Graves’ Disease”
(RISG) Study. The first part, termed RISG1 (prospective
cohort-study), aimed to investigate how and when individual
patients with newly diagnosed GH enter remission during
ATD treatment and to study the usefulness of regular TSH-
receptor antibodies (TRAb) measurement during treatment.
The primary outcome of the second part of the study (RISG2)
was to compare, in a randomized approach, the effects of
a low-dose block-replace treatment versus no treatment, on
keeping patients in remission once remission is achieved.
2. Methods
The inclusion and study protocol have been described in
detail previously [14]. In brief, newly diagnosed GH patients
were recruited from two Danish endocrine referral centers
in Aalborg (Aalborg University Hospital) and Copenhagen
(Herlev University Hospital) between January 2007 and June
2011.The populations were considered mildly iodine deficient
in Aalborg and borderline iodine deficient in Copenhagen
[15]. Consecutive patients with TSH < 0.01 mU/L, total T3
above 3.0 nmol/L, and TRAb ≥ 1.0 IU/L or diffuse increased
uptake on a thyroid scintigram were invited. Patients were
included if the above measurements were confirmed in a
subsequent blood sample. Exclusion criteria were age below
18 years, pregnancy or deliverywithin the previous 12months,
severe comorbidity, imminent or manifest thyroid storm,
patients with moderate or severe Graves’ orbitopathy consid-
ered for immunosuppressive therapy, prior ablative treatment
for Graves’ disease, treatment with antithyroid medication
within 24 months, or known intolerance of methimazole
(MMI) or propylthiouracil (PTU). Procedures at inclusion
were blood sampling, thyroid ultrasonography, and recording
of thyroid related eye signs and symptoms. Furthermore, the
patients completed a questionnaire regarding history of thy-
roid disease, medication including estrogen and nutritional
supplements, smoking habits, comorbidities, and presence of
thyroid disease in relatives.
The study was approved by the local ethical commit-
tee North Denmark Region Committee on Health Research
Ethics (VN-20060062) and registered in ClinTrial.gov
(NCT00796913). All the patients provided informed consent.
Blood sampleswere drawn at baseline and after 2-3weeks,
5-6 weeks, 2 months, 3 months, 4 months, and every second
month hereafter until remission or until 24 months after
inclusion. The initial ATD dose was MMI 10 mg three times,
10 mg two times, or 15 mg once daily according to whether
the initial total T3 level was > 2 or 1.4 – 2 or 1.2 – 1.3 times
above the upper reference limit of T3, respectively.
In vivo kinetic studies on ATD have shown dose equiva-
lence between MMI and PTU of 1:15 [16]. In our experience,
and hence being applied in the protocol for this study, a dose
equivalence of 1:20 has proven to be clinically preferable. So,
an equivalent dose of 5 mg MMI was 100 mg PTU. We report
PTU doses in MMI dose-equivalents.
Remission was defined as TSH > 0.4 mU/L and TRAb
≤ 1. 0 IU/L in a patient receiving a methimazole dose ≤ 5
mg/day, on twooccasions twomonths apart.Thepatientswho
entered remission were subsequently invited to participate
in the randomized open-label study (termed RISG2), in
which the patients were randomized to either continuous
fixed low-dose antithyroid drug treatment (FLATD) or just
observation. FLATD was MMI 5 mg/day in combination
with L-T4 of 1 microgram/bodyweight in kilogram/day. Dose
adjustments were only made on the L-T4 dose, in order to
maintain normal TSH. In this part of the study, the patients
were followed until relapse or for 24 months. Relapse was
defined as TSH < 0.01 mU/L and total T3 ≥ 3.0 nmol/L
and TRAb ≥ 1.0 IU/L. The patients were investigated at
randomization and after completing the study and had
regular blood samples taken at the time of randomization and
after 1, 3, 6, 9, 12, 18, and 24 months. At the investigations
the patients underwent the same procedures as performed
at baseline. Figure 1 shows an overview of the inclusion
from the prospective observation study (RISG1) until the
end of the randomized study (RISG2). During the study,
the patients were seen at routine clinical controls and were
contacted regularly in order to preserve compliance with the
randomization arm procedure and blood samplings and for
registration of possible adverse events.
3. Assays
At the time of the study, the clinical routine at the two
centers was to use total T4 and total T3 levels for diagnosing
and treating thyroid disease, with a single measurement of
thyroxine-binding globulin (TBG) or a T3-test to evaluate
thyroid hormone binding capacity. Serum total T4 concen-
tration (reference range: 60–140 nmol/L, in both involved
laboratories), serum total T3 (reference range: Aalborg 1.1–2.5
nmol/L, Copenhagen 1.0–2.6 nmol/L), and serum TSH (ref-
erence range: Aalborg 0.30–4.5mU/L, Copenhagen 0.40–4.0
mU/L) were measured by standard high capacity analytical
platforms (Aalborg, RocheDiagnostics Elecsys; Copenhagen,
Immulite 2500, chemiluminescent enzyme immunoassay).
TRAb was measured using a receptor assay (DYNOtest
TRAK, Thermo Fisher, Berlin, Germany). TRAb ≥ 1.0 IU/L
was considered TRAb positive [17]. TPO-Ab detection limit
was 30 kU/L by KRYPTOR antibody tests (Thermo Fisher,
Berlin, Germany) [17]. Urinary iodine was determined by
the Ceri/Arsenium method after alkaline ashing [18, 19] and
expressed as crude concentrations (𝜇g/L).
3.1. Statistical Analysis. Data were analyzed using IBM SPSS
statistics version 24.0 (Armonk, New York, USA). Mann-
Whitney U and Wilcoxon signed rank (nonparametric) tests
were used for comparisons between groups and within
groups on numeric data. Chi square or Fisher’s exact test was
used on categorical data. The log rank test was used to test for
differences on the Kaplan-Meyer survival analysis. Multiple
logistic regression analyses were performed with remission
as dependent categorical variable and the significant variables
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Figure 1: Flow chart of the inclusion process comprising the two substudies RISG1 (predictor of attaining remission) and RISG2 (comparing
relapse rates in patients randomized to observation or fixed low dose antithyroid drug treatment; FLATD).
in Table 1 as independent variables. Area under curve (AUC)
calculationswere used for studying differences on the receiver
operating characteristic (ROC) curves at different TRAb cut-
off levels (TRAb equal to or lower than 5, 7, 10, 15, or 20 IU/L)
and age cut-off levels (age equal to or lower than 40, 45, 50,
or 55 years). A p value < 0.05 was considered as statistically
significant.
4. Results
A total of 208 patients were included. Table 1 shows the
patients’ characteristics and the results of the thyroid function
tests and antibody levels at baseline for the 173 (83.2%)
patients who completed the first part of the study protocol
(RISG1) at the two centers. Most patients were recruited
in Aalborg (80%) with comparable completion rates of
83 % at the two centers. The reasons for not completing
RISG1 were noncompliance (15 patients), development of
severe orbitopathy (7 patients), moving out of the area (4
patients), side effects of MMI/PTU (4 patients), development
of major comorbidity (3 patients), hemithyroidectomy due
to follicular neoplasia (1 patient), and pregnancy (1 patient).
Median (IQR) age, TRAb level, and T4 level at baseline for
the excluded patients were 48 (31–54) years, 12 (5.8–16.8)
IU/L, and 202 (179–233) nmol/L, respectively. One patient
was TRAb negative and one had a missing TRAb value at
baseline.
Twenty-nine patients (17%) in RISG1 and 11 (17%) in
RISG2 used oral contraceptives or estrogen supplements.The
median (interquartile range, IQR) of the thyroid hormone
levels at baseline in these patients was as follows: total T4 235
(204–312) nmol/L, total T3 5.8 (4.4–8.2) nmol/L, compared
to total T4 205 (171–256) nmol/L, total T3 5.4 (4.0–7.0) in
nonestrogen users. The median (interquartile range, IQR)
level of TBG was 26.0 (20.5–31.5) mg/L in the estrogens
user and 18.0 (16.0–22.0) mg/L in the nonestrogen users.
Patients using oral contraceptives or estrogen supplements
were excluded from the statistical analyses when total T4 or
total T3 was included.
Ninety-two patients entered remission during RISG1
(Figure 1) and willing patients (n = 66) were subsequently
randomized to either observation without treatment (n= 33,
Arm A) or FLATD (n= 33, Arm B). The patients’ charac-
teristics at the time of randomization are seen in Table 2.
One patient in arm A was excluded due to withdrawal of
consent, whereas 5 patients were excluded in arm B (1 due to
withdrawal of consent, 1 due to inability to follow the blood-
sample protocol, 1 due to development of joint pain, 1 due to
pregnancy, and 1 death (due to metastasizing cholangiocarci-
noma diagnosed 3 months after randomization)). Regarding
adverse events, none were registered in the observation
group. Two patients (6%) were registered with adverse events
in the treatment group, one patient developed joint pain and
was excluded from the study, and one had a skin rash, which
disappeared when the L-T4 tablet was switched to another
brand.
4.1. Predictors of Remission (RISG1). The median (IQR) ob-
servation time was 22 (12-24) months and 92 patients (53.2
%) entered remission after a median (IQR) of 13 (10–17.75)
months. The patients entering remission were comparable to
the nonremission patients on all parameters (Table 1) except
they had lower concentrations of TRAb and lower T4 levels,
were younger, and had higher BMI, at baseline. The signif-
icant parameters were entered as independent variables in
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Figure 2: Event curve of patients achieving remission depending
on whether initial TRAb was below (black) or above (grey) 10 IU/L.
Remission was TRAb < 1.0 IU/L and TSH ≥ 0.40 mU/L on a MMI
dose of 5 mg or less per day evaluated twice, two months apart.
a multivariate logistical regression model with remission as
dependent variable. In this model, only low TRAb (p= 0.005)
and younger age (p=0.013) were associated with remission as
an outcome, with odds ratios 1.047 (95% CI: 1.014–1.081) and
1.033 (95%CI: 1.007–1.060), per unit, respectively. Thus, a 35-
year-old patient with initial TRAb of 5 IU/L had an odds ratio
of entering remission of 1.6 compared to a 55-year-old with
initial TRAb of 10 IU/L.
In order to examine which TRAb and age value were
the strongest predictor of remission, several ROC curves and
corresponding AUC values were calculated (data not shown).
The cut-off point of TRAb at 10 IU/L showed the highest
AUC (0.652), but still the sensitivity and specificity were
rather low at 0.57 and 0.74, respectively. An event curve for
entering remission depending on whether the baseline TRAb
value was below or above this cut-off of 10 IU/L is shown
in Figure 2. After 24 months of observation, 63.3% (n=62)
of the patients with a baseline TRAb value below 10 IU/L
entered remission, whereas only 39.4% (n=28) with a baseline
TRAb value above 10 IU/L entered remission. Themean time
of entering remission was 16.4 vs. 21.5 months (log rank,
p=<0.001) in patients with TRAb below vs. above 10 IU/L,
respectively. TRAb was significantly lower at 6.6 (4.0–12) vs.
10 (7.2–18) IU/L (p<0.001) among the 37.6% of patients who
had one or more elevated TSH measurements (indicator of
overtreatment) during the study. Receiving 5 mg MMI or
less per day was a prerequisite in the definition of remis-
sion. We thus calculated which of the 16 consecutive TRAb
measurements were most informative in patients receiving
5 mg MMI or less per day, in order to identify patients in
remission. In such patients, TRAb measurements at 6 or 8
months identified remission in 48% and 46%, respectively.
When subdividing such patients according to initial TRAb
level, TRAb measurements at 6 months identified remission
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Figure 3: Kaplan-Meyer curve of relapse of Graves’ hyperthy-
roidism in patients randomized to either fixed low dose block-
replace treatment (grey) or just observation (black).
in 56% in patients with initial TRAB below 10 and in 13%with
initial TRAB above 10 IU/L. At time points other than 6 or 8
months, a TRAb measurement only identified remission in
around 20%, with no major difference between patients with
initial TRAb below or above 10 IU/L.
4.2. Risk of Relapse (RISG2). Significantly more patients
completing the study had relapse in the group randomized
to observation as 11 out of 32 (34.4 %) patients had relapse
in this group compared to only 1 out of 28 (3.6%) in the
group randomized to treatment (Chi2, p < 0.003). Figure 3
shows the event curve of risk of relapse in the two arms. The
mean time to relapse was significantly longer in the treatment
arm (observation, arm A, 20.1 (17.4–22.8); treatment, arm B,
23.3 (22.0–24.6) months, log rank p= 0.003). None of the
parameters in Table 2, TRAb levels at the time of diagnosis
or time to achieve remission in RISG1 were significantly
different between the patients who experienced relapse and
patients in lasting remission. After the randomization, thy-
roid volume was coincidently different between the two
groups (Table 2). In a multivariate logistic model (relapse as
dependent variable, thyroid volume and treatment arm as
independent variables) treatment arm (p < 0.003; odds ratio,
13 (95 % CI: 1.5–108)) was the only significant parameter.
When only patients completing the study (per protocol
analysis) were studied, the same results were found (data not
shown).
5. Discussion
TRAb is a hallmark of GH. It is a diagnostic marker of the
disease [20], a prognostic marker of relapse after remission
[7, 21], and a risk marker of developing Graves’ orbitopathy
[22]. With the present study we confirmed that TRAb was
a prognostic marker and showed that patients with lower
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TRAb were at higher risk of overtreatment (elevated TSH).
However, it was not possible to make more advanced models
to better predict remission, by including further parameters
including smoking, GD in relatives, or a close follow-up by
multiple TRAb measurements. Different predictive scoring
systems were proposed for calculation of risk of relapse in
Graves’ disease after antithyroid treatment [23–25].When the
individual components of these scores were evaluated thyroid
volume and fT4 level were the significant parameters in the
Italian Clinical Severity Score [25]. In the Dutch GREAT
score, younger age, high fT4, higher TRAb, and presence of
goiter were the significant parameters [23]. In an external
validation study of the GREAT score, performed by Struja et
al., only higher TRABvaluewas significant in themultivariate
analysis [24]. The AUC in these studies were between 0.60
and 0.67 and comparable to 0.65 as found in the present study,
where only a simple stratification on TRAb below or above 10
mU/L was used.
The generally used definition of remission in GH is “the
patients has not experienced relapse of Graves’ disease 12
months after stopping ATD” [4]. This definition is retro-
spective and is thus difficult to apply into clinical use when
treating patients with GH, as the clinician would prefer to
ascertain remission before treatment is withdrawn. Using a
definition of remission founded on measurable parameters
could enable shorter treatment duration based on individual
response to treatment. We used a definition of remission as
TRAb < 1.0 IU/L and TSH ≥ 0.40 mU/L on a MMI dose
of 5 mg or less per day evaluated twice, two months apart.
In patients randomized to 24 months of observation after
entering remission, 66% were still in remission after 2 years
of observation. The remission rate found in other prospective
studies on patients with GD treated with ATD was highly
variable, ranging from 20 to 70% [23, 26–39].Themajority of
these studies showed remission rates between 40 and 70 %,
but quite diverse definitions of remission were used. TRAb
is probably a relevant element in a definition of current
remission in GH. Measuring TRAb every second month as
performed in this study is presumably not cost efficient.
However, we showed that, in patients with initial TRAb below
10 IU/L, approximately 50%would be in remission (according
to the definition above) after 6 to 8 months if the patient
had normal TSH on a MMI dose of 5 mg or less per day for
the previous two months. Patients in remission according to
this criterion randomized to either observation or continuous
low dose ATD treatment experienced relapse in 34% or
3.6% of the cases during a 24-month follow-up period. The
continuous low dose ATD combined with L-T4 treatment
option was well tolerated and with significant lower relapse
rate than just observation and could thus be a worthwhile
option in patients where a relapse rate of 34% is unacceptable.
The study had some limitations. We used total thyroid
hormone measurements as opposed to free T4 and free
T3 measurements. However, we measured protein-binding
capacity in all patients and as different assays were used in the
two centers, treatment and diagnostic cut-off were according
to magnitudes of the reference limits of the particular assays,
thus increasing the external validity of the results. Free
thyroid hormone immunoassays are not without analytical
pitfalls and show considerable between-assay differences [40,
41]. Also, most of the conclusions of the study are based on
TSH and TRAb measurement, while T4 and T3 values were
secondary parameters. In order to further identify relevant
risk factors for remission or relapse a more comprehensive
clinical work-up and the use of genetic markers could have
been valuable [23]. Although the second part of the study was
randomized, it was not blinded. The lack of blinding intro-
duces the risk of judging potential adverse effects skewed.
Overall, the adverse event rate was very low and the lack
of blinding probably had an only negligible effect on the
conclusions.
This study addresses several relevant issues when treating
GH with ATD. Based on the results from the present study a
rational approach to thyroid function testing (TFT, meaning
TSH and T3 or T4) and TRAb measurements in patient
treated with ATD for GH could be as follows: at the time of
diagnosis: measure TFT and TRAb. At this time point TRAb
is a diagnostic marker and a TRAb level below 10 IU/L is
a risk marker of overtreatment and a favorable marker of
attaining remission.Measurement of TFT every 4-6weeks for
the first 4months and every second to third months hereafter
is sensible. Patients with baseline TRAb below 10 IU/L may
well have a TRAb measurement performed at the time point
6-8 months if TSH is normal on a MMI equivalent dose of ≤
5 mg/day. Around 50% of such patients would have a TRAb
level below 1.0 IU/L and a likely relapse rate of 34% for the
following 24 months if treatment is stopped even after this
short treatment duration.
In conclusion, this study showed that TRAb measured
at the time of diagnosing GH was a prognostic marker of
attaining remission of the disease, but also a risk marker
for overtreatment. Consecutive TRAb measurements during
treatment were not worthwhile, but a single measurement of
TRAb after 6-8 months in patients with initial TRAb < 10
IU/L who have normal TSH on a daily MMI dose of 5 mg or
less per day could substantially shorten the treatment period
in around 50% of these patients. Lastly, we showed that, in
patients in remission, only 3.6% experienced relapse during
24 months of follow-up when treated with a fixed dose of 5
mg MMI in combination with L-T4 supplement. A relapse
rate significantly lower than the 34% was seen in the patients
randomized to no treatment.
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